Presenter beware
Executive Summary
FDA is freezing clinical development of an investigational cancer drug based on trial results presented at the American Society of Clinical Oncology June 3. Under the clinical hold, Telik stops treatment with Telcyta (canfosfamide) in trials after two studies in second-line advanced platinum refractory or resistant ovarian cancer and one study in third-line NSCLC failed to show benefit with treatment...
You may also be interested in...
IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: